Trogenix Secures £70 Million Series A to Accelerate Next-Generation Cancer Gene Therapies
Edinburgh-based biotech firm Trogenix Ltd has secured a significant £70 million (approximately US $95 million) Series A financing round to accelerate its pipeline of potentially…